Latest Updates in the Treatment and Management of Psoriatic Arthritis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Lilly USA, LLC

Description:
Psoriatic arthritis is a debilitating disease that may affect up to 1 million adult men and women in the United States. Psoriatic arthritis is highly underdiagnosed and is a progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations. Patients often experience fatigue, extreme joint pain, permanent joint damage and dysfiguration that may affect their quality of life, physical function, and ability to work. Approximately 30% to 40% of people with psoriasis will also develop psoriatic arthritis and diagnosis may be easier to confirm if psoriasis coexists with symptoms of arthritis however signs of psoriatic arthritis appear before symptoms of psoriasis. Measuring rheumatoid factor and anti–cyclic citrullinated peptide (anti-CCP) may aid in diagnosis. Looking for key characteristics and patterns of the disease in addition to reviewing the patient’s medical history and utilizing magnetic resonance imaging (MRI) and x-rays of the involved joints, along with a dermatologic evaluation may be used to diagnose psoriatic arthritis. Traditional treatment includes the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) which can reduce inflammation, pain, swelling and stiffness. Many of the medications suppress the immune system and lead to a potential increase risk of infections. Newer biologic treatments have been developed and block the IL-12 and IL-23 proteins to help with the disease. Secukinumab is a novel biologic which blocks IL-17A to help reduce inflammation and is given by a subcutaneous injection and is producing promising results that treat the skin and arthritis.

Upon completion of this activity, participants will be able to:

  • Analyze the mechanisms of action of new pharmacologic therapies for the treatment of psoriatic arthritis (PsA) and current clinical evidence regarding their efficacy and safety

  • Examine the immunological targets of available and emerging immune-based therapies for PsA

  • Assess individualized treatment plans for patients with PsA that take into account the risks and benefits of newer agents

  • Explore the latest clinical updates for the optimal treatment of patients with PsA

  • Identify strategies to overcome barriers related to comorbidities as well as their implication on the choice of treatment options
     

Faculty: Joseph Markenson, MD
Attending Physician
Hospital for Specialty Surgery
Professor of Clinical Medicine
Weill Cornell Medical College

Disclosure:

Dr. Markenson serves on an advisory board for AbbVie, BMS, Celgene, Lilly, Novartis, Pfizer, and Regeneron. He serves on the speaker's bureau for AbbVie, BMS, Celgene, Lilly, Novartis, Pfizer, and Regeneron. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Lilly USA, LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue